Amino acid substitution mutants of interleukin 13
AssigneeThe Pennsylvania State Research Foundation
InventorWaldemar Debinski
Life of this patent
Estimating the term…
Abstract
This invention provides mutant hIL13 molecules include those made by substituting one or more of the amino acid residues that occur in the alpha-helix regions of native hIL13 with various other amino acid residues. Multiply mutated forms of hIL13 conjugated to cytotoxins are used to preferentially target diseased cells over non-diseased cells.
Claims48
A purified mutant hIL13 molecule comprising an amino acid sequence (a) having at least 90% sequence identity to the native hIL13 sequence (SEQ ID NO:1) and (b) differing from the native hIL13 sequence by at least a first amino acid substitution occurring in the A alpha helix and a second amino acid substitution occurring in the D alpha helix.
A purified mutant hIL13 molecule comprising an amino acid sequence (a) having at least 90% sequence identity to the native hIL13 sequence (SEQ ID NO:1) and (b) differing from the native hIL13 sequence by at least three amino acid substitutions.
A purified mutant hIL13 molecule, wherein the molecule comprises a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs:2-9.
A purified mutant hIL13 molecule, wherein the molecule consists of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs:2-9.
A purified nucleic acid encoding a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:2-9.
The method of claim 40, wherein the effector molecule is selected from the group consisting of a cytotoxin, a detectable label, an antibody, a liposome, and a lipid.
The method of claim 40, wherein the effector molecule comprises a radionuclide.
Dependencies are inferred from the claim text.